The purpose of this study was to investigate the association of tumor tissue and plasma miR-146a/b expressions with the clinicopathological properties and overall survival (OS) in surgical patients with intrahepatic cholangiocarcinomas (ICC).
Introduction
Intrahepatic cholangiocarcinomas (ICC), with the second highest incidence of all liver cancer accounting for the proportion of 5% to 20%, is a critical threat imperiling people's health worldwide. [1, 2] In the last 2 decades, accumulating evidence revealed that the morbidity and mortality caused by ICC are increasing gradually over the world. [3] Multiple elements are involved in the development and progression of ICC, among which the main risk factors consist of cholangiolithiasis, hepatitis B virus (HBV) infection, and Clonorchis sinensis infection, as well as primary sclerosing cholangitis (PSC). [3] [4] [5] Despite great improvements of early diagnosis, optimal treatments (eg, surgery, chemotherapy, and radiotherapy), as well as patients' care, the prognosis of ICC is still far from satisfaction, the 5-year survival rate of ICC patients with complete resection is only 20% to 40%. [6, 7] microRNAs (miRNAs), belonging to a great family of small endogenous non-coding RNAs, regulate target genes and protein expression via binding to the 3 0 -untranslated regions (3 0 -UTRs) directly. [8] miRNAs contribute to multiple molecule activities, such as cell proliferation, differentiation, migration, and apoptosis. [9, 10] Accumulating evidence has defined miRNAs as biomarkers in various carcinomas, including colorectal cancer, gastric cancer, breast cancer, and lung cancer. [11] [12] [13] [14] microRNA-146 family (miR-146) consists of miR-146a and miR-146b, both of them have the similar sequences in the mature miRNAs excluding 2 bases toward the 3 0 -end. [15] Dysregulated miR-146 expression has been described in a variety of malignant tumors, such as gastric cancer, breast cancer, or even hepatocellular cancer. [16] [17] [18] However, few studies about the effects of miR-146 expression on the prognosis of ICC patients have been explored. Therefore, the purpose of this study was to investigate the association of tumor tissue and plasma miR-146 a/b expressions with the clinicopathological properties and overall survival (OS) in surgical patients with ICC.
Methods

Patients
Eighty No patient received neo-adjuvant systemic therapy before the operation, and after the surgery, all the patients received adjuvant therapy with catheter radiofrequency ablation, or chemotherapy by gemcitabine plus cis-platinum, and/or radiotherapy.
This study was approved by Ethics Committee of The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology; the written informed consents were obtained from all patients.
Clinicopathological features and follow-ups
Clinical and pathological properties of ICC patients at baseline were collected including age, gender, hepatitis B surface antigen (HBsAg) status, hepatic C virus (HCV) status, smoke, drink, differentiation, TNM stage, and ECOG performance status. The median follow-up duration was 31 months, and the last followup date was January 2017. OS was calculated from the date of surgery to patients' death or last follow-up.
Sample collection and RNA extraction
Tumor tissue samples were obtained during the surgery. Blood samples were collected before the operation and plasma were separated. Total RNA was then extracted from the samples with TRIzol reagent (Invitrogen) according to the instructions of the manufacturer.
miR-146a/b determination by qPCR
Total RNA was extracted from tumor tissue and plasma samples by Trizol LS kit (TaKaRa, Japan), and RNA was subjected to reverse transcription by utilizing the PrimerScript Real-time reagent kit (TaKaRa, Japan). Subsequently, miR-146 a/b expressions were quantitated by SYBR Premix Ex TaqTM II (TaKaRa, Japan). The primer sequences (BGI, China) for the primer source were performed as follows: hsa-miR-146a-5p RT primer: 5 0 -CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAA CCCATG-3 0 ; hsa-miR-146a-5p Forward primer: 5 0 -ACACTC-CAGCTGGGTGAGAACTGAATTCCATG-3 0 ; hsa-miR-146a-5p Revert: 5 0 -TGTCGTGGAGTCGGCAATTC-3 0 ; hsa-miR146b-5p RT primer; 5 0 -ACACTCCAGCTGGGTGAGAACT-GAATTCCATG-3 0 ; hsa-miR-146b-5p Forward primer: 5 0 -ACACTCCAGCTGGGTGAGAACTGAATTCCATA-3 0 ; hsamiR-146b-5p Revert: 5 0 -TGTCGTGGAGTCGGCAATTC-3 0 . The expression levels of miR-146a/b were calculated by using the 2 -△△t method and U6 served as the internal reference.
Statistics
Statistics was carried out using SPSS 22.0 (IBM) and 2010 office software (Microsoft). Correlation of miR-146a/b expression in tissue and plasma sample, as well as miR-146a/b expression with clinicopathological features were determined by Spearman test. Kaplan-Meier curves and log-rank test were used to compare OS in different groups. Univariate and multivariate Cox regression were used to evaluate the baseline predictive factors for OS in ICC surgical patients. P <.05 was considered significant.
Results
Patients characteristics
The median age was 57.0 (53.0-65.0) years, male and female were 58 (67%) and 29 (33%) ( Table 1) . Thirty-two (37%) patients were HBsAg positive and 10 (11%) patients were HCV Table 1 Baseline clinicopathological characteristics of ICC patients (N = 87). 
Items
Correlation between miR-146a/b in tumor tissue and plasma
Correlations of miR-146a/b in tumor tissue and plasma were evaluated in Figure 1 . miR-146a (R = 0.376, P < .001, Fig. 1A ) and miR-146b (R = 0.291, P = .006, Fig. 1B ) expressions in tumor tissue were positively associated with that in plasma.
Correlation of miR-146a/b with clinical and pathological features
As listed in Table 1 , miR-146a expressions in tissue and plasma samples were observed to be 2.123 (1.117-4.666) and 1.397 (1.101-1.650), respectively, whereas miR-146b expressions were 3.267 (2.065-5.214) in tissue samples, and 1.332 (1.059-1.553) in plasma samples. As presented in Table 2 , tissue miR-146a was negatively correlated with age (R = À0.225, P = .036), poor differentiation (R = À0.250, P = .020), N stage (R = À0.249, P = .020), and TNM stage (R = À0.286, P = .007), as well as ECOG performance (R = À0.282, P = .008), whereas plasma miR-146a was inversely associated with N stage (R = À0.314, P = .003), TNM stage (R = À0.318, P = .003), and ECOG performance (R = À0.271, P = .011). Moreover, tissue miR146b was negatively correlated with gender (R = À0.217, P = .043) and T stage (R = À0.214, P = .047), and plasma miR-146b was negatively associated with smoke (R = 0.228, P = .034).
Tissue/plasma miR-146a correlated with prolonged OS but not miR-146b
In terms of miR-146a, its high expression in both tumor tissue (P < .001, Fig. 2A ) and plasma (P = .029, Fig. 2B ) were correlated with prolonged OS compared with low expression. Nevertheless, no association of miR-146b expression in tumor tissue (P = .187, Fig. 2C ) or plasma (P = .336, Fig. 2D ) with OS was discovered in the present study.
Tissue miR-146a independently predicted longer OS
Univariate Cox proportional hazards regression was used to evaluate the baseline predictive factors for OS in ICC surgical patients, as presented in Table 3 , which indicated that miR-146a high expression in tissue (P < .001) and in plasma (P = .035) were Data was presented as R coefficient and P value. Correlation was determined by Spearman test. P <.05 was considered significant. ECOG = Eastern Cooperative Oncology Group, HBsAg = hepatitis B surface antigen, HCV = hepatic C virus, ICC = intrahepatic cholangiocarcinoma.
Zhang et al. Medicine (2017) 96:44 www.md-journal.com associated with better OS. Besides, poor differentiation (P = .045), higher T stage (III/IV) (P < .001), higher N stage (I) (P = .005), higher M stage (I) (P = .048), increased TNM stage (III/IV) (P = .001), and elevated ECOG performance status (1/2) (P = .007) were correlated with worse OS in surgical patients with ICC. Furthermore, ICC patients treated with catheter radiofrequency ablation compared with chemo(radio) therapy seemed to be associated with better OS, but without statistical significance (P = .234).
All factors with a P value <.1 were further analyzed by the multivariate Cox proportional hazards regression model. It revealed that the high expression of tissue miR-146a (P = .001) but not plasma miR-146a (P = .076) was an independent factor for prolonged OS, whereas higher T stage (III/IV) (P = .002) and evaluated ECOG performance status (1/2) (P = .021) could predict worse OS in ICC surgical patients independently (Table 4 ).
Discussion
In the present study, we found that both miR-146a and miR-146b expressions in tumor tissue were positively associated with that in plasma; and tumor tissue miR-146a was negatively correlated with age, poor differentiation, N stage, and TNM stage, as well as ECOG performance, whereas plasma miR-146a was inversely associated with N stage, TNM stage, and ECOG performance. As to miR-146b, only tumor tissue was negatively associated with gender and T stage. Both tissue miR-146a and plasma miR-146a were associated with better OS, whereas only tissue miR-146a high expression was an independent factor for prolonged OS of ICC patients, and T stage (III/IV)) and ECOG performance status (1/2) predict worse OS independently. ICC, one of the multifactorial malignancies, originates from the epithelial cells of the intrahepatic bile duct beyond secondorder branches. [19] The most common pathological process of ICC is chronic inflammation and fibrosis of bile duct, which could induce epithelial cells apoptosis and proliferation. Subsequently, this repeated process lead to aberrant molecule activities, stimulating tumorigenesis. [1] miR-146a, encoded on chromosome 5(5q33.3), [16] has been disclosed as a potential tumor repressor in several malignant tumors. Upregulation of miR-146a inhibits lung cancer cell proliferation and differentiation via mediating the macrophage migration inhibitory factor (MIF) gene and NF-kB signaling pathway. [20] Also, its overexpression represses gastric cancer cell migration by reducing the UHRF1 level via targeting its 3 0 -UTR, resulting in the inhibition of tumor invasion and metastasis subsequently. [21] Additionally, miR-146a expression has been observed to be positively associated with antitumor immune systems by targeting signal transducer and activator of transcription 3 (STAT3) in human hepatocellular carcinoma (HCC) cells. [22] Analysis of miR-146a in triple-negative breast cancer (TNBC) tumors has been observed to predict better OS by regulating breast cancer 1 (BRCA1) expression. [23] As to tissue miR-146, it is considered as a suppressor of HCC, negatively associated with the clinical TNM stage, metastasis, and portal vein tumor embolus, as well as a number of tumor nodes. [24] Furthermore, increased expression of tissue miR-146a has been confirmed to predict a higher survival rate of gastric cancer, esophageal squamous cell carcinoma and non-small cell lung cancer (NSCLC), as well as renal cell carcinoma (RCC). [25] [26] [27] [28] These researches suggest that miR-146a acts as tumor suppressor on malignant tumors, and it is correlated with better prognosis. Partially in line with these results, our study found that tumor tissue miR-146a was negatively correlated with poor differentiation, N stage, and TNM stage, as well as ECOG performance, whereas plasma miR-146a was inversely associated with N stage, TNM stage, and ECOG performance. This might arise from the inhibition of cell proliferation, differentiation, and migration by miR-146a through regulating several pathways. [20, 23] In addition, we also found that high expressions of tissue miR-146a and plasma miR-146a were associated with better OS, whereas only tissue miR-146a high expression was an independent factor for prolonged OS of ICC patients. There are 2 possible reasons. First, miR-146a inhibits tumor growth and metastasis by mediating various molecule activities [21, 22] ; second, miR-146a increases the sensitivity of chemotherapy, radiotherapy, and targeted therapy, decreasing recurrence of ICC patients. [29] [30] [31] [32] miR-146b, consisting of miR-146b-5p and miR-146b-3p, is located on human chromosome 10 at position q24.32. [33] Published studies have defined miR-146b as a tumor inhibitor in various carcinomas, including esophageal cancer, gallbladder cancer and thyroid cancer. [34] [35] [36] A larger number of studies have elucidated the role of miR-146b in carcinoma cell lines. In a study of esophageal cancer cell, miR-146b acted as a tumor suppressor by targeting CCAAT/enhancer-binding proteins b liver-enriched transcriptional activator protein 2 (C/EBPb LAP2) to inducing cell proliferation and repressing cell apoptosis. [36] In addition, miR-146b expression was associated with the TNM stage, liver metastasis and differentiated degree, and its overexpression showed better OS in patients with gallbladder cancer (GBC). [35] These studies illustrates that miR-146b serves as tumor suppressor on the prognosis of carcinomas. On the other hand, miR-146b expression could also act as tumor promoter to inducing thyroid cancer cell migration and invasion by downregulating zinc and ring finger 3 (ZNRF3). [37] However, our study showed that no association of plasma and tissue miR-146b with OS in ICC surgical patients. The possible reasons are that the dual effects of miR-146b on both promotion and repression of malignant tumors. Meanwhile, we also observed that tumor tissue miR-146b was only negatively correlated with T stage, this might result from the repression of cell proliferation and apoptosis via targeting several genes. [36, 38] Several limitations still existed in this study. The sample size was relatively small. The plasma miR-146a/b expression of healthy people was not evaluated to compare with ICC patients. The follow-up duration was relatively short with median value 31 months. Further study with larger sample size and longer followup duration is necessary to be carried out in the future.
In conclusion, both plasma and tissue miR-146a expression correlated with favorable OS, whereas only tissue miR-146a was an independent prognostic biomarker in surgical patients with ICC.
